Mitosol® Receives Key Reimbursement Assurance for 2015

Share Article

Center for Medicare and Medicaid Services Renews Mitosol® Reimbursement

Mobius Therapeutics has received a renewal of reimbursement for Mitosol® (mitomycin for solution) Kit for Ophthalmic Use in 2015. After reviewing the final OPPS/ASC rule from the Center for Medicare and Medicaid Services (CMS) regarding 2015 reimbursement, Mitosol® will continue to receive a separate, pass-through reimbursement at 106% of the Average Sales Price (ASP). The full updated CMS reimbursement schedule for hospital out-patient prospective payment can be found here; the published rate for reimbursement of J7315 as of 1 January 2015 is $372.80.

"As Mitosol® remains the only approved formulation of mitomycin-c bearing an ophthalmic indication, this continuation of reimbursement supports federal regulatory guidance related to the use of approved formulations,” said Ed Timm, President and CEO of Mobius Therapeutics. “When regulatory guidance and economics align, patients and providers win. As Medicare payment remains unchallenged, we are seeing broad adoption of this same payment policy from private payors. This reaffirmation will assure existing and new Mitosol® patients and providers economic security. Access to Mitosol® will meet their on-going needs, both clinical and financial,” said Timm.

About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Please see full prescribing information at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ed Timm
Visit website